Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus TREXALL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus TREXALL.
METHOTREXATE SODIUM PRESERVATIVE FREE vs TREXALL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with DNA synthesis, repair, and cellular replication. It also inhibits thymidylate synthase and purine biosynthesis, and has immunosuppressive and anti-inflammatory effects mediated by adenosine release.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, preventing the conversion of folic acid to tetrahydrofolate, thereby inhibiting DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and release of adenosine.
15-25 mg once weekly orally or intramuscularly for rheumatoid arthritis; 50-75 mg/m2 once weekly intravenously for single-agent acute lymphoblastic leukemia maintenance; 50 mg/m2 intravenously every 2-4 weeks for ectopic pregnancy; 30-40 mg/m2 intravenously once weekly for psoriasis. Dosing varies by indication.
Oral: 7.5-15 mg once weekly; subcutaneous: 7.5-15 mg once weekly for rheumatoid arthritis; may be increased up to 25-30 mg weekly based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life is 8-15 hours at standard doses; with high-dose therapy (>1 g/m²), half-life extends to 12-24 hours due to saturation of excretion pathways and potential third-space accumulation.
Terminal elimination half-life is 3-10 hours; for high-dose methotrexate, half-life is 8-15 hours. Clinically, monitoring at 24, 48, and 72 hours is standard to guide leucovorin rescue
Primarily renal (80-90% excreted unchanged via glomerular filtration and active tubular secretion). Biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal elimination is minor (<10%)
Category D/X
Category C
Antimetabolite
Antimetabolite